sciendo

Eur. Pharm. J. 2022, 69(1), S1-S5.
ISSN 1338-6786 (online) and ISSN 2453-6725 (print version),
DOI: 10.2478/afpuc-2022-0001

EUROPEAN PHARMACEUTICAL JOURNAL

Supplement: The Evaluationof Cardiovascular Risk in Diabetic Patients

Table 1S. Baseline characteristic of patients.

Baselina data at V1	**Mean ± SEM (min.–max.)**
Age (years)	62.72 ± 0.68 (36–84)
BMI (kg/m^2)	33.16 ± 0.39 (24.09–47.38)
Diabetes length (years)	7.97 ± 0.32 (2.00–21.00)
Biochemical parameters	
Fasting glycaemia (mmol/l)	9.46 ± 0.21 (4.90–19.47)
HbA1c (%)	8.67 ± 0.10 (4.90–13.40)
LDL (mmol/l)	2.56 ± 0.07 (0.66–5.26)
HDL (mmol/l)	1.26 ± 0.03 (0.74–2.86)
TAG (mmol/l)	2.34 ± 0.19 (0.44–30.91)
Total cholesterol (mmol/l)	4.70 ± 0.08 (2.75–10.48)
Albumin (g/l)	42.50 ± 0.19 (36.00–48.70)
Creatinine (µmol/l)	46.40 ± 1.62 (46.40–169.20)
Albumin/creatinine	2.09 ± 0.04 (1.13–4.10)
Physical parameters	
SBP (mmHg)	150.72 ± 1.58 (100–200)
DBP (mmHg)	82.06 ± 0.74 (55–116)
HR (/min)	80.15 ± 0.64 (46–122)

comorbities at V1	**% of patients in study (n = 179)**
Smokers	12%
Hypertension	75%
Dyslipidaemia	78%
Kidney disorders	19%
Neuropathy	27%
Retinal disorders	19%
Ischaemic heart disease	0.6%
Heart failure	2.3%
Pankreatitis	1.2%
Arrhytmia	0.6%
Cancer	1.2%
Myocardial infarction	1.2%
Stroke	1.2%

BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, HR – heart rate, HDL – high-density lipoprotein, LDL – low-density lipoprotein, TAG – triacylglycerol, SEM – standard error of mean

Table 2S. Baseline data of the patients according to gender,

Parameter/gender		*n*	Mean ± std error of the mean	Minimum	Maximum
Cardiovascular parameters					
SBP (mmHg)	Women	101	149.52 ± 2.07	100.00	200.00
	Men	78	151.92 ± 2.27	109.00	190.00
DBP (mmHg)	Women	101	80.39 ± 0.92*	55.00	110.00
	Men	78	84.10 ± 1.13	55.00	116.00
HR (/min)	Women	101	80.14 ± 0.87	48.00	122.00
	Men	78	79.91 ± 0.88	46.00	100.00
Parameters of diabetes compensation					
Glycaemia (mmol/l)	Women	101	9.09 ± 0.25	4.90	16.00
	Men	78	10.76 ± 0.96	5.17	19.47
HbA1c (%)	Women	101	8.6 ± 0.1	6.3	13.4
	Men	78	8.7 ± 0.2	4.9	12.2
BMI and lipid profile					
BMI (kg/m^2)	Women	101	33.34 ± 0.50	24.09	47.38
	Men	78	33.09 ± 0.62	24.28	47.32
Total cholesterol (mmol/l)	Women	101	4.70 ± 0.10	2.75	7.48
	Men	78	4.71 ± 0.13	2.88	10.48
HDL (mmol/l)	Women	101	1.27 ± 0.03	0.74	2.01
	Men	78	1.24 ± 0.04	0.67	2.86
LDL (mmol/l)	Women	101	2.55 ± 0.10	0.66	5.26
	Men	78	2.59 ± 0.10	0.95	4.76
TAG (mmol/l)	Women	101	2.05 ± 0.09	0.85	4.56
	Men	78	2.67 ± 0.40	0.44	30.91
Renal parameters					
Albumin (g/l in the current urine sample)	Women	101	42.31 ± 0.24	36.50	48.70
	Men	78	42.65 ± 0.28	36.00	48.50
Creatinine (µmol/l in the current urine sample)	Women	101	84.15 ± 1.91*	42.50	145.90
	Men	78	94.24 ± 2.60	62.00	169.20

p* **< 0.05 v*ersus m***en**
BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, HR – heart rate, HDL – high-density lipoprotein, LDL – low-density lipoprotein, TAG – triacylglycerol

Table 3S. Glycaemic compensation of patients according to gender and treatment.

HbA1c levels in treated groups			*n*	Mean	Std. error	Minimum	Maximum
Gender	**Parameter**	**Treatment**					
Women	V1_HbA1c	DPP4i	15	7.71	0.23	6.60	9.50
		SU + DPP4i	23	8.38	0.29	6.30	11.40
		SU + SGLT	21	8.26	0.30	7.00	13.40
		INZ + DPP4i	18	9.22*	0.22	7.40	11.30
		INZ + SGLT	19	9.30*	0.35	6.70	12.20
	V2_HbA1c	DPP4i	15	6.93	0.17	6.00	8.20
		SU + DPP4i	23	7.69	0.30	5.60	11.10
		SU + SGLT	21	7.17	0.31	3.30	9.80
		INZ + DPP4i	18	8.47*+	0.27	6.30	10.50
		INZ + SGLT	19	8.91*+	0.35	7.10	12.40
Men	V1_HbA1c	DPP4i	9	7.17	0.36	4.90	8.50
		SU + DPP4i	25	8.40^{z}	0.19	6.80	10.20
		SU + SGLT	10	8.78^{x}	0.42	7.20	10.30
		INZ + DPP4i	18	9.57^{x}	0.28	7.60	12.20
		INZ + SGLT	15	9.20^{x}	0.37	6.70	11.70
	V2_HbA1c	DPP4i	9	7.04	0.36	5.70	9.40
		SU + DPP4i	25	7.40	0.33	4.60	11.40
		SU + SGLT	10	8.12	0.59	5.41	10.60
		INZ + DPP4i	18	8.67	0.34	6.60	11.90
		INZ + SGLT	15	8.19	0.43	6.50	12.00

*Women: *p < 0.05 versus DPP4i, $^{+}$p < 0.05 versus SU + SGLT; men: ^{x}p < 0.05 versus DPP4i, ^{z}p < 0.05 versus INZ + DPP4i*
DPP4i – dipeptidyl peptidase-4 inhibitor, SGLT2 – sodium–glucose co-transporter-2

Table 4S. HbA1c levels – comparison between men and women.

Treatment		Gender	*n*	Mean	Std. error mean	*p*-Value
DPP4i	V1_HbA1c	Women	15	7.71	0.23	
		Men	9	7.17	0.36	0.225
	V2_HbA1c	Women	15	6.93	0.17	
		Men	9	7.04	0.36	0.785
SU + DPP4i	V1_HbA1c	Women	23	8.38	0.29	
		Men	25	8.40	0.19	0.950
	V2_HbA1c	Women	23	7.69	0.30	
		Men	25	7.40	0.33	0.516
SU + SGLT	V1_HbA1c	Women	21	8.26	0.30	
		Men	10	8.78	0.42	0.323
	V2_HbA1c	Women	21	7.17	0.31	
		Men	10	8.12	0.59	0.174
INZ + DPP4i	V1_HbA1c	Women	18	9.22	0.22	
		Men	18	9.57	0.28	0.341
	V2_HbA1c	Women	18	8.47	0.27	
		Men	18	8.67	0.34	0.656
INZ + SGLT	V1_HbA1c	Women	19	9.30	0.35	
		Men	15	9.20	0.37	0.846
	V2_HbA1c	Women	19	8.91	0.35	
		Men	15	8.19	0.43	0.201

DPP4i – dipeptidyl peptidase-4 inhibitor, SGLT2 – sodium–glucose co-transporter-2

Table 5S. Cardiovascular risk in patients according to treatment and gender.

Treatment	CVD risk	Gender	*n*	Mean ± std. error	Minimum	Maximum	*p*
DPP4i	CHD	Women	15	13.33 ± 2.22	5.50	35.80	0.100
		Men	9	28.79 ± 6.16	8.90	61.00	
	Fatal CHD	Women	15	9.61 ± 2.07	2.80	30.60	0.027
		Men	9	22.38 ± 6.11	3.80	55.50	
	Stroke	Women	15	10.21 ± 2.16	1.60	29.70	0.108
		Men	9	18.61 ± 5.44	2.00	46.20	
	Fatal stroke	Women	15	1.52 ± 0.35	0.20	5.10	0.050
		Men	9	3.43 ± 1.05	0.30	8.60	
SU + DPP4i	CHD	Women	23	15.70 ± 2.55	3.20	63.60	0.003
		Men	25	28.44 ± 3.14	10.60	68.00	
	Fatal CHD	Women	23	12.09 ± 2.50	1.70	60.50	0.022
		Men	25	21.83 ± 3.18	5.50	63.60	
	Stroke	Women	23	10.64 ± 2.39	2.30	58.60	0.074
		Men	25	19.16 ± 3.89	1.30	73.60	
	Fatal stroke	Women	23	1.77 ± 0.46	0.30	11.30	0.067
		Men	25	3.34 ± 0.68	0.30	11.90	
SU + SGLT	CHD	Women	21	15.63 ± 1.96	1.40	35.10	0.006
		Men	10	30.98 ± 6.46	5.00	70.90	
	Fatal CHD	Women	21	12.21 ± 1.81	0.50	33.10	0.019
		Men	10	24.64 ± 6.31	1.50	65.70	
	Stroke	Women	21	13.05 ± 2.37	1.10	50.70	0.272
		Men	10	19.93 ± 7.48	0.80	82.40	
	Fatal stroke	Women	21	2.14 ± 0.39	0.20	7.60	0.243
		Men	10	3.37 ± 1.27	0.10	13.70	
INZ + DPP4i	CHD	Women	18	21.41 ± 2.01	8.00	41.30	0.001
		Men	18	32.81 ± 2.41	18.00	57.80	
	Fatal CHD	Women	18	17.27 ± 1.90	5.30	37.60	0.007
		Men	18	25.77 ± 2.30	10.80	46.20	
	Stroke	Women	18	13.89 ± 1.81	4.40	31.50	0.162
		Men	18	21.57 ± 5.06	3.90	92.90	
	Fatal stroke	Women	18	2.36 ± 0.33	0.70	6.40	0.120
		Men	18	4.08 ± 1.03	0.50	16.80	
INZ + SGLT	CHD	Women	19	19.68 ± 2.24	6.20	46.20	0.002
		Men	15	34.12 ± 3.95	14.70	61.50	
	Fatal CHD	Women	19	15.54 ± 2.18	2.80	41.60	0.012
		Men	15	26.27 ± 3.59	9.40	53.40	
	Stroke	Women	19	11.66 ± 2.28	1.10	35.90	0.133
		Men	15	16.44 ± 1.96	7.20	34.10	
	Fatal stroke	Women	19	2.17 ± 0.47	0.10	8.60	0.274
		Men	15	2.89 ± 0.40	0.80	5.80	

CHD – coronary heart disease, DPP4i – dipeptidyl peptidase-4 inhibitor, SGLT2 – sodium–glucose co-transporter-2